Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119702 | 0.77 | RXFP1 (0.44) | LMNATMIGD3ADORA2AADORA1ADORA3 | |
| SCHEMBL16119696 | 0.77 | MAPT (0.41) | LMNAADORA3RXFP1MAOBMAPT | |
| SCHEMBL16119593 | 0.72 | ELANE (0.42) | TMIGD3ADORA2AADORA1ADORA3MAOB | |
| SCHEMBL19593077 | 0.70 | LIMK1 (0.51) | LMNAMAPTTP53CYP1A2KDM4E | |
| SCHEMBL16119534 | 0.69 | THRB (0.51) | LMNATMIGD3RXFP1MAOBMAPT | |
| SCHEMBL17517709 | 0.69 | TP53 (0.55) | LMNAMAPTTP53CYP1A2THRB | |
| SCHEMBL16119589 | 0.68 | MAPT (0.45) | LMNAADORA3MAOBMAPTTP53 | |
| SCHEMBL16119633 | 0.67 | RXFP1 (0.45) | LMNAADORA2AADORA1ADORA3RXFP1 | |
| SCHEMBL16119543 | 0.67 | MAOB (0.46) | TMIGD3ADORA2AADORA1ADORA3RXFP1 | |
| SCHEMBL16119689 | 0.66 | TP53 (0.74) | LMNARXFP1MAOBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014152213-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | CFTR, SLC47A1, ABCB11 | LMNA 1837/4885TMIGD3 1397/4885ADORA2A 4553/4885 |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | HSP90B1, HSPD1, HSPE1 | LMNA 1729/4885TMIGD3 2748/4885ADORA2A 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.